RECRUITING Phase 1 ClinicalTrials.gov

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Sponsor: Nuvalent Inc. • ClinicalTrials.gov ID: NCT06521554

Registry updated: 2026-10-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-small lung cancer (NSCLC). Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL-330 in participants with advanced or metastatic HER2 mutant NSCLC.

Interventions

NVL-330 (Drug)
Oral Tablet of NVL-330

Eligibility criteria

Inclusion Criteria: 1. Age ≥ 18 years 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC 3. Documented HER2 status as follows: 1. Phase 1a: Documented oncogenic HER2 mutation such as HER2 exon20 insertion mutations or single nucleotide variants or HER2 amplification. 2. Phase 1b: Documented oncogenic HER2 mutation. 4. Identification of lesions as follows: 1. Phase 1a: Must have evaluable disease (target or nontarget) according to RECIST 1.1. 2. Phase 1b: Must have measurable disease, defined as ≥ 1 radiologically measurable target lesion according to RECIST 1.1. 5. Adequate organ function and bone marrow reserve Exclusion Criteria: 1. Participant's cancer has known oncogenic driver alteration other than HER2 2. Known allergy/hypersensitivity to excipients of NVL-330 3. Major surgery within 4 weeks of the first dose of study drug 4. Ongoing or recent anticancer therapy 5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study

Conditions

Locally Advanced Solid Tumor Metastatic Solid Tumor

Locations

City of Hope - Lennar — Irvine, California, United States
University of California, Davis Comprehensive Cancer Center — Sacramento, California, United States
Stanford Cancer Institute — Stanford, California, United States
Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States
Georgetown University Medical Center — Washington D.C., District of Columbia, United States
Sibley Memorial Hospital — Washington D.C., District of Columbia, United States
Sylvester Comprehensive Cancer Center — Miami, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center — Baltimore, Maryland, United States
Massachusetts General Hospital — Boston, Massachusetts, United States
Henry Ford Cancer Center — Detroit, Michigan, United States
Washington University — St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
OSU Brain and Spine Hospital — Columbus, Ohio, United States
SCRI Oncology Partners — Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
NEXT Virginia — Fairfax, Virginia, United States
Fred Hutchinson Cancer Center — Seattle, Washington, United States
Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia
North Shore Health Hub — Saint Leonards, New South Wales, Australia
Cross Cancer Institute — Edmonton, Alberta, Canada
Princess Margaret Cancer Center - University Health Network — Toronto, Ontario, Canada

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment